Incyte Corporation
$115.39
−1.48 · −1.26% today
Market open · updated 12:18:50 PM ET
- High
- $118.33 5:45 AM
- Low
- $116.42 5:30 AM
Against the S&P 500 Price change through Oct 28, 2026
INCY+18.33%
S&P 500+13.26%
INCY+27.52%
S&P 500+12.41%
INCY+122.44%
S&P 500+88.06%
INCY+77.78%
S&P 500+68.51%
Key numbers
- Previous close
- $116.87
- Open
- $111.64
- Day's range
- $111.01 – $117.08
- 52-week range
- $89.25 – $132.60
- Volume
- 1.3 million
- Average volume
- 1.7 million
- Market value
- $23.4 billion
- Price to earnings
- 14.4last 12 months
- Earnings per share
- $8.05last 12 months
- Beta
- 0.74moves less than the market
- Dividend
- None
- 50-day average
- $120.86
- 200-day average
- $107.92
Thursday, Oct 29, 2026, before the open.
Analyst price targets and the full financials are in the terminal.
Who Incyte competes with From our value chain
Incyte in the news
No desk stories on INCY yet. When we write about it, the story leads this list.
- HeadlineIncyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs TranscriptSeeking Alpha · October 27, 2026 at 4:49 AM ET
- HeadlineIncyte Highlights Promising Early Data for '890 and '734 in GI CancersMarketBeat · October 26, 2026 at 10:02 PM ET
- HeadlineIncyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyZacks Investment Research · October 26, 2026 at 12:26 PM ET
- HeadlineIncyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026Business Wire · October 26, 2026 at 9:45 AM ET
- HeadlineIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness Wire · October 24, 2026 at 7:00 AM ET
- HeadlineIncyte Gears Up to Report Q3 Earnings: Will Results Disappoint?Zacks Investment Research · October 23, 2026 at 10:26 AM ET
- HeadlinePrelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte OptionMarketBeat · October 22, 2026 at 11:02 PM ET
- HeadlineAnalysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out forZacks Investment Research · October 22, 2026 at 11:02 AM ET
Earnings
Next report: Thursday, Oct 29, 2026, before the open.
Congress trades in INCY
1 purchase and 1 sale in the latest 2 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 4, 2026 | Oct 9, 2026 |
| Rob BresnahanHouse | Sale | $1,001 - $15,000 | May 15, 2025 | Jun 2, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Incyte
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,844
- Headquarters
- Wilmington, Delaware
- Website
- incyte.com
- Listed
- Nov 4, 1993
More biotechnology stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.